Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
US regulators on Thursday approved Repatha, the second injectable drug of its kind designed for certain patients with stubbornly high cholesterol which puts them at risk of heart disease.
Repatha, also known as evolocumab, is made by Amgen and is part of a new class of drugs known as PCSK9 inhibitors, or antibodies which work on the liver to lower cholesterol.
It was approved by the US Food and Drug Administration for people with inherited conditions that cause high levels of low-density lipoprotein (LDL), or bad cholesterol, as well as people whose clogged arteries have led to heart disease.
High LDL cholesterol in the blood causes plaque buildup in the arteries and eventually heart disease, which is the leading cause of death for Americans killing 610,000 people every year.
https://uk.news.yahoo.com/us-approves-injectable-anti-cholesterol-drug-repatha-220235792.html
Repatha, also known as evolocumab, is made by Amgen and is part of a new class of drugs known as PCSK9 inhibitors, or antibodies which work on the liver to lower cholesterol.
It was approved by the US Food and Drug Administration for people with inherited conditions that cause high levels of low-density lipoprotein (LDL), or bad cholesterol, as well as people whose clogged arteries have led to heart disease.
High LDL cholesterol in the blood causes plaque buildup in the arteries and eventually heart disease, which is the leading cause of death for Americans killing 610,000 people every year.
https://uk.news.yahoo.com/us-approves-injectable-anti-cholesterol-drug-repatha-220235792.html